tiprankstipranks
Trending News
More News >
Novo Nordisk (DE:NOV)
XETRA:NOV
Germany Market

Novo Nordisk (NOV) Stock Forecast & Price Target

Compare
334 Followers
See the Price Targets and Ratings of:

NOV Analyst Ratings

Moderate Buy
14Ratings
7 Buy
5 Hold
2 Sell
Based on 14 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NOV Stock 12 Month Forecast

Average Price Target

€88.97
▲(51.52% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €88.97 with a high forecast of €134.02 and a low forecast of €44.23. The average price target represents a 51.52% change from the last price of €58.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"€43","66":"€66","89":"€89","112":"€112","135":"€135"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134.024,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€134.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.9718324,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€88.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.22792,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€44.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,66,89,112,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.34,64.16184615384616,69.98369230769231,75.80553846153846,81.62738461538461,87.44923076923077,93.27107692307692,99.09292307692309,104.91476923076922,110.73661538461539,116.55846153846153,122.3803076923077,128.20215384615386,{"y":134.024,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.34,60.696294800000004,63.052589600000005,65.4088844,67.7651792,70.121474,72.4777688,74.83406360000001,77.19035840000001,79.54665320000001,81.90294800000001,84.2592428,86.6155376,{"y":88.9718324,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.34,57.25445538461539,56.16891076923077,55.08336615384616,53.99782153846154,52.912276923076924,51.82673230769231,50.74118769230769,49.65564307692308,48.570098461538464,47.484553846153844,46.39900923076923,45.31346461538462,{"y":44.22792,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":117.381,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.634,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.904,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.811,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.967,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.524,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.016,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.294,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.016,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€134.02Average Price Target€88.97Lowest Price Target€44.23
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Berenberg Bank
€81.75
Hold
39.23%
Upside
Reiterated
05/16/25
J.P. Morgan
€134.02
Buy
128.24%
Upside
Reiterated
05/16/25
Morgan Stanley
€80.41€73.71
Hold
25.53%
Upside
Reiterated
05/12/25
Goldman Sachs
€110.57€103.87
Buy
76.89%
Upside
Reiterated
05/12/25
Deutsche Bank
€100.52
Buy
71.18%
Upside
Reiterated
05/08/25
DZ BANK AG
Hold
Reiterated
05/08/25
UBS
€100.52€93.82
Buy
59.77%
Upside
Reiterated
05/08/25
Bank of America Securities
€121.96€113.92
Buy
94.01%
Upside
Reiterated
05/07/25
Kepler Capital
€84.44
Buy
43.79%
Upside
Reiterated
05/07/25
Bernstein
€83.09
Hold
41.51%
Upside
Reiterated
05/07/25
Jefferies
€55.62
Sell
-5.28%
Downside
Reiterated
05/07/25
DBS
€44.23
Sell
-24.68%
Downside
Downgraded
04/24/25
Barclays
€120.62€93.82
Buy
59.77%
Upside
Reiterated
04/16/25
Stifel Nicolaus
€104.54€93.82
Hold
59.77%
Upside
Downgraded
03/03/25
Guggenheim
€106.55€106.95
Buy
82.14%
Upside
Reiterated
01/17/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Berenberg Bank
€81.75
Hold
39.23%
Upside
Reiterated
05/16/25
J.P. Morgan
€134.02
Buy
128.24%
Upside
Reiterated
05/16/25
Morgan Stanley
€80.41€73.71
Hold
25.53%
Upside
Reiterated
05/12/25
Goldman Sachs
€110.57€103.87
Buy
76.89%
Upside
Reiterated
05/12/25
Deutsche Bank
€100.52
Buy
71.18%
Upside
Reiterated
05/08/25
DZ BANK AG
Hold
Reiterated
05/08/25
UBS
€100.52€93.82
Buy
59.77%
Upside
Reiterated
05/08/25
Bank of America Securities
€121.96€113.92
Buy
94.01%
Upside
Reiterated
05/07/25
Kepler Capital
€84.44
Buy
43.79%
Upside
Reiterated
05/07/25
Bernstein
€83.09
Hold
41.51%
Upside
Reiterated
05/07/25
Jefferies
€55.62
Sell
-5.28%
Downside
Reiterated
05/07/25
DBS
€44.23
Sell
-24.68%
Downside
Downgraded
04/24/25
Barclays
€120.62€93.82
Buy
59.77%
Upside
Reiterated
04/16/25
Stifel Nicolaus
€104.54€93.82
Hold
59.77%
Upside
Downgraded
03/03/25
Guggenheim
€106.55€106.95
Buy
82.14%
Upside
Reiterated
01/17/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

Which Analyst Should I Follow If I Want to Buy DE:NOV and Sell After:
1 Month
xxx
Success Rate
34/57 ratings generated profit
60%
Average Return
+1.29%
reiterated a xxx
rating 18 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.65% of your transactions generating a profit, with an average return of +1.29% per trade.
3 Months
xxx
Success Rate
22/33 ratings generated profit
67%
Average Return
+5.64%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +5.64% per trade.
1 Year
Emily FieldBarclays
Success Rate
25/33 ratings generated profit
76%
Average Return
+23.09%
reiterated a buy rating last month
Copying Emily Field's trades and holding each position for 1 Year would result in 75.76% of your transactions generating a profit, with an average return of +23.09% per trade.
2 Years
xxx
Success Rate
34/57 ratings generated profit
60%
Average Return
+22.51%
reiterated a xxx
rating 18 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 59.65% of your transactions generating a profit, with an average return of +22.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOV Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
9
14
20
26
27
Buy
29
26
25
15
8
Hold
19
19
17
15
12
Sell
8
8
4
5
5
Strong Sell
0
0
0
0
0
total
65
67
66
61
52
In the current month, NOV has received 35 Buy Ratings, 12 Hold Ratings, and 5 Sell Ratings. NOV average Analyst price target in the past 3 months is 88.97.
Each month's total comprises the sum of three months' worth of ratings.

NOV Financial Forecast

NOV Earnings Forecast

Next quarter’s earnings estimate for NOV is €0.80 with a range of €0.72 to €0.85. The previous quarter’s EPS was €0.88. NOV beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.27% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.
Next quarter’s earnings estimate for NOV is €0.80 with a range of €0.72 to €0.85. The previous quarter’s EPS was €0.88. NOV beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.27% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.

NOV Sales Forecast

Next quarter’s sales forecast for NOV is €10.46B with a range of €9.87B to €10.92B. The previous quarter’s sales results were ―. NOV beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.80% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.
Next quarter’s sales forecast for NOV is €10.46B with a range of €9.87B to €10.92B. The previous quarter’s sales results were ―. NOV beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.80% of the time in the same period. In the last calendar year NOV has Outperformed its overall industry.

NOV Stock Forecast FAQ

What is DE:NOV’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is 88.97.
    What is DE:NOV’s upside potential, based on the analysts’ average price target?
    Novo Nordisk has 51.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Novo Nordisk a Buy, Sell or Hold?
          Novo Nordisk has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 5 hold ratings and 2 sell ratings.
            What is Novo Nordisk’s share price target?
            The average share price target for Novo Nordisk is 88.97. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €134.02 ,and the lowest forecast is €44.23. The average share price target represents 51.52% Increase from the current price of €58.72.
              What do analysts say about Novo Nordisk?
              Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of Novo Nordisk?
                To buy shares of DE:NOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis